JP2017506894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506894A5 JP2017506894A5 JP2016553321A JP2016553321A JP2017506894A5 JP 2017506894 A5 JP2017506894 A5 JP 2017506894A5 JP 2016553321 A JP2016553321 A JP 2016553321A JP 2016553321 A JP2016553321 A JP 2016553321A JP 2017506894 A5 JP2017506894 A5 JP 2017506894A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- engineered
- inhibitor
- nucleotide sequence
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 57
- 239000000427 antigen Substances 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 53
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 210000003289 regulatory T cell Anatomy 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 13
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 12
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000003211 malignant effect Effects 0.000 claims description 9
- 102100031780 Endonuclease Human genes 0.000 claims description 8
- 108010042407 Endonucleases Proteins 0.000 claims description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 230000007018 DNA scission Effects 0.000 claims description 6
- 230000000415 inactivating effect Effects 0.000 claims description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- -1 CD78 Proteins 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 4
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 4
- 102100034872 Kallikrein-4 Human genes 0.000 description 4
- 102100035721 Syndecan-1 Human genes 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108010024383 kallikrein 4 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 2
- 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 101710117995 B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 101150031358 COLEC10 gene Proteins 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102000013392 Carboxylesterase Human genes 0.000 description 2
- 108010051152 Carboxylesterase Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 108010036395 Endoglin Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102100023721 Ephrin-B2 Human genes 0.000 description 2
- 108010044090 Ephrin-B2 Proteins 0.000 description 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 2
- 101150032879 Fcrl5 gene Proteins 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 102100028113 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000916625 Homo sapiens Granulocyte-macrophage colony-stimulating factor receptor subunit alpha Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101100396742 Homo sapiens IL3RA gene Proteins 0.000 description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000994322 Homo sapiens Integrin alpha-8 Proteins 0.000 description 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 101000891028 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP11 Proteins 0.000 description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102100032825 Integrin alpha-8 Human genes 0.000 description 2
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 241000712902 Lassa mammarenavirus Species 0.000 description 2
- 108010028275 Leukocyte Elastase Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- 102100040348 Peptidyl-prolyl cis-trans isomerase FKBP11 Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102100040120 Prominin-1 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
- 102000007000 Tenascin Human genes 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 101800000385 Transmembrane protein Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 150000002339 glycosphingolipids Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100508818 Mus musculus Inpp5k gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101100366438 Rattus norvegicus Sphkap gene Proteins 0.000 description 1
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010079891 prostein Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201470088 | 2014-02-21 | ||
| DKPA201470088 | 2014-02-21 | ||
| PCT/EP2015/053592 WO2015124715A1 (en) | 2014-02-21 | 2015-02-20 | Method for in situ inhibition of regulatory t cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506894A JP2017506894A (ja) | 2017-03-16 |
| JP2017506894A5 true JP2017506894A5 (enExample) | 2018-03-29 |
| JP6665102B2 JP6665102B2 (ja) | 2020-03-13 |
Family
ID=50158998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553321A Active JP6665102B2 (ja) | 2014-02-21 | 2015-02-20 | 制御性ｔ細胞をインサイチューで阻害するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10196608B2 (enExample) |
| EP (1) | EP3107552B1 (enExample) |
| JP (1) | JP6665102B2 (enExample) |
| AU (1) | AU2015220762B2 (enExample) |
| CA (1) | CA2939711C (enExample) |
| WO (1) | WO2015124715A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
| US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| JP6665102B2 (ja) * | 2014-02-21 | 2020-03-13 | セレクティスＣｅｌｌｅｃｔｉｓ | 制御性ｔ細胞をインサイチューで阻害するための方法 |
| MX380176B (es) | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| KR20170017916A (ko) | 2014-05-13 | 2017-02-15 | 추가이 세이야쿠 가부시키가이샤 | 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자 |
| US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| WO2016034666A1 (en) * | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| EP3262166A4 (en) | 2015-02-24 | 2018-08-15 | The Regents of The University of California | Binding-triggered transcriptional switches and methods of use thereof |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| JP6931329B2 (ja) * | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| EP3378488A4 (en) * | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| US11052111B2 (en) * | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| WO2017193059A1 (en) * | 2016-05-06 | 2017-11-09 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| CA3034093A1 (en) | 2016-08-23 | 2018-03-01 | The Regents Of The University Of California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018052142A1 (ja) * | 2016-09-16 | 2018-03-22 | キッセイ薬品工業株式会社 | 遺伝子改変細胞及びその作製方法 |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| ES2665543B1 (es) * | 2016-10-26 | 2019-02-12 | Fundacion Para La Investig Medica Aplicada | Péptidos de unión a FOXP3 y usos de los mismos |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| EP3585398A4 (en) | 2017-02-23 | 2020-08-19 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| EP4759318A2 (en) | 2017-04-14 | 2026-06-17 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| AU2018288863A1 (en) * | 2017-06-22 | 2020-01-30 | Board Of Regents, The University Of Texas System | Methods for producing regulatory immune cells and uses thereof |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| WO2019094983A1 (en) * | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN111867619A (zh) | 2018-01-03 | 2020-10-30 | 曲生物制品公司 | 过继性细胞治疗的先天寻靶 |
| ES3068176T3 (en) * | 2018-02-12 | 2026-05-28 | Massachusetts Gen Hospital | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN111349606A (zh) * | 2018-12-20 | 2020-06-30 | 上海恒润达生生物科技有限公司 | P60抑制剂与cart细胞联合应用 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN113811329B (zh) | 2019-04-19 | 2025-10-14 | 天科雅生物科技有限公司 | 抗pd-1抗体和其用途 |
| EP3747904A1 (en) * | 2019-06-03 | 2020-12-09 | Universität Regensburg | Cd25-specific chimeric antigen receptors and their uses |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4341300A1 (en) * | 2021-05-21 | 2024-03-27 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| WO2023133442A2 (en) * | 2022-01-06 | 2023-07-13 | Cedars-Sinai Medical Center | Protac molecules targeting foxp3 and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2328776B1 (es) * | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| WO2014130635A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| JP6665102B2 (ja) * | 2014-02-21 | 2020-03-13 | セレクティスＣｅｌｌｅｃｔｉｓ | 制御性ｔ細胞をインサイチューで阻害するための方法 |
-
2015
- 2015-02-20 JP JP2016553321A patent/JP6665102B2/ja active Active
- 2015-02-20 US US15/120,060 patent/US10196608B2/en active Active
- 2015-02-20 EP EP15706446.0A patent/EP3107552B1/en active Active
- 2015-02-20 AU AU2015220762A patent/AU2015220762B2/en active Active
- 2015-02-20 WO PCT/EP2015/053592 patent/WO2015124715A1/en not_active Ceased
- 2015-02-20 CA CA2939711A patent/CA2939711C/en active Active
-
2018
- 2018-03-16 US US15/923,771 patent/US20180208896A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508468A5 (enExample) | ||
| RU2016139643A (ru) | Способ создания т-клеток, пригодных для аллогенной трансплантации | |
| Xue et al. | Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy | |
| US20220339193A1 (en) | Modified Cell Expressing Therapeutic Agent and Uses thereof | |
| AU2015220762B2 (en) | Method for in situ inhibition of regulatory T cells | |
| KR102618231B1 (ko) | 변형된 만능성 줄기 세포, 및 제조 및 사용 방법 | |
| US20220378911A1 (en) | Use of Triplex CMV Vaccine in CAR T Cell Therapy | |
| JP7252135B2 (ja) | 遺伝子療法 | |
| JP2019047801A (ja) | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 | |
| US20210100841A1 (en) | Presenting cell and use thereof in cell therapy | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| US20190000878A1 (en) | Lymphocyte Cell Lines and Uses Thereof | |
| US11739136B2 (en) | Inducible dominant negative PD-1 and uses in adoptive cell therapy | |
| WO2023141472A2 (en) | Engineered immune cells with enhanced potency and uses of same in immunotherapy | |
| US11981920B2 (en) | Modified cell with enhanced migration capability | |
| WO2019129850A1 (en) | Off-the-shelf engineered cells for therapy | |
| EP3892720A1 (en) | Presenting cell and use thereof in cell therapy | |
| US20220031747A1 (en) | Foxp1-ablated chimeric cells | |
| US20240269182A1 (en) | Modified Chimeric Antigen Receptor and Use thereof | |
| MHC et al. | MHC Dextramer® Reagents | |
| KR20250127134A (ko) | 조작된 자연 살상 세포 및 관련 방법 | |
| NZ741052A (en) | Antibody/t-cell receptor chimeric constructs and uses thereof |